The SNMMI Clinical Trials Network provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Increased standardization in trials leads to better data that then results in expanded utilization of radiopharmaceuticals.
The Clinical Trials Network (CTN) was formed in 2008 by SNMMI to help facilitate the effective use of molecular imaging radiopharmaceuticals in clinical trials. Benefits to the drug development industry include access to a registry of qualified imaging sites and biomarker manufacturers, a robust scanner validation program, access to standardized imaging protocols and clinical research education and training for site personnel. Our Mission is to advance the use of molecular imaging biomarkers in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging biomarkers during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. We also maintain a comprehensive registry that stores and manages information on imaging sites, production sites and those sites that have both imaging and production capabilities. To access or add your site to the CTN Site Registry, click here.
Meetings and webinars provide the ideal venue to promote and support standardization in imaging, especially when part of a research trial. The Clinical Trials Network sponsors two major sessions per year during the SNMMI Mid-Winter and Annual Meetings. The CTN Site Orientation and Education Committee and other consultants plan the programs keeping in mind the audience and the ever-evolving landscape of nuclear medicine and molecular imaging. Clinical research basics remain fairly constant but are often not part of the education and training that many molecular imaging personnel receive. To that end, the CTN has developed an outstanding curriculum covering a wide-range of research topics.
Download a PDF Registration Form
The CTN serves a unique and critical function in SNMMI. By working closely with sponsors, associations and agencies, CTN members help to advance key initiatives for standardization in PET/CT clinical imaging. The purpose of the internship program is to identify and train future leaders of SNMMI in the structure, governance and operations of the organization; to prepare individuals for progressive levels of responsibility; and to ensure effective leadership that advances the mission and goals of the organization.
Interns serve a two-year term that begins and ends at the SNMMI Annual Meetings. A mentor is appointed by the CTN Leadership for the intern, to work with the intern and supervise special projects and activities. During the two years, the intern is expected to attend the CTN Leadership and Committee meetings at the SNMMI Mid-Winter and Annual Meetings, and participate in conference calls. Financial support is provided by the CTN in the form of reimbursement for travel expenses and meeting registration.
If you are interested is applying for the CTN intern position, please email us at email@example.com.
Lance Burrell, MS, CNMT, ARRT(CT) (2013-2015)
We are very pleased to welcome Lance Burrell as the CTN intern for 2013-2015. In his intern application, Lance stated that “The pursuit of professional fulfillment is a life-long and complex journey.” Currently employed at the Huntsman Cancer Institute at the University of Utah, Lance pursues his journey by working in a busy academic environment where clinical research is a major aspect of his day-to-day responsibilities. In line with these duties, Lance will spend part of his internship to help refine methods and practices in improving quality and consistency in research imaging. As a CTN intern, his goal is to learn from the vast experience and knowledge of those currently in leadership roles within the CTN and SNMMI and to increase his ability and value in mentoring future young professionals.
Xiaofei Wang, MD, PhD (2011-2013)
Xiaofei Wang, MD, PhD, served as a CTN intern for 2011-2013. As the first CTN intern, Dr. Wang provided valuable assistance with our centralized IND program and acted as a liaison for the CTN with the Chinese Nuclear Medicine Society. When his internship ended, Dr. Wang continued on as a member of the CTN Site Qualification and Monitoring Committee, including reviewing patient images submitted by study sites under our centralized IND for FLT.
The Clinical Trials Network would like to hear from you.
We are an organization of molecular imaging experts, from physicians and physicists to scientists and technologists. Many are pioneers in the field of nuclear medicine and molecular imaging. If you need assistance in incorporating molecular imaging into a therapeutic trial or want to study a new radiopharmaceutical, our team of experts can assist you with all phases of a clinical trial. From scanner validation, trial design assistance, and study personnel training, the CTN has programs to ensure that you are utilizing molecular imaging effectively and efficiently. To obtain more information about our specific programs or events, please contact us at firstname.lastname@example.org.
The Clinical Trials Network strives to provide the community with as much information as possible on its projects, programs and overall goals within the context of this website. Often, some questions or topics require additional clarification, which we address through this Frequently Asked Questions page. We realize, however, that there still may be some areas in which the public would like additional information. If your question was not answered on our website or the main SNMMI website, please feel free to submit the question using the link/form below.
CTN works collaboratively with SNMMI Councils and Chapters as well as with external groups to move the entire field forward. In working with other imaging associations such as RSNA, government agencies such as the FDA and industry leaders, the CTN envisions having a key role in advancing the use of radiopharmaceuticals and optimizing the use of molecular imaging in clinical trials and for dissemination into clinical practice.
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The 68Ga Users Group was formed to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. Recently, SNMMI received orphan drug designation for Ga-68 DOTATOC.
Click here to see the slides from the Gallium Information Session held in St. Louis during the SNMMI Annual Meeting on June 9th, 2014.
The Pediatric Brain Tumor Consortium (PBTC), which was formed by the NCI in 1999, is devoted to the study of correlative tumor biology and new therapies for primary CNS tumors of childhood. PET imaging is incorporated into many PBTC protocols and is supervised by the PBTC Neuro-Imaging Group. This group is collaborating with the CTN, utilizing our unique brain phantom to evaluate images acquired on study scanners and analyze the results.
This 5-year project, begun in September of 2012, is working to identify and implement harmonized PET reconstruction parameters for all PET/CT scanners for use in clinical trial scenarios where quantitative accuracy is critical. The CTN plays a key administrative role and provides imaging infrastructure to the study group.
To learn more about the activities of the CTN,
Posters - CTN submitted posters
Presentations - a selection of research topics
Publications - by and about the CTN
The Dawn of in vivo Tau Imaging
FDA Inspections: What You Can Expect
Who’s Who in Clinical Research
CTN Completes Audits on FLT Manufacturing Sites